2020-12-10 · Opiant Pharmaceuticals News: This is the News-site for the company Opiant Pharmaceuticals on Markets Insider

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2020 Results - Earnings Call Transcript seekingalpha.com - August 9 at 8:10 AM: Opiant Pharmaceuticals EPS beats by $0.19, beats on revenue seekingalpha.com - August 6 at 9:08 PM: Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update 2021-04-05 A high-level overview of Opiant Pharmaceuticals, Inc. (OPNT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 2021-03-22 NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call … 2021-04-05 2021-04-13 About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose. The National Institute on Drug Abuse, a component of the NIH, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. 2021-03-15 About us Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. Share Price & News. How has Opiant Pharmaceuticals's share price performed over time and what events caused price changes?

Opiant pharmaceuticals news

10.61 0.03 (0.28%) Upgrade to Real-Time Regular Market . Proxy Statement - Merger or Acquistion (preliminary) (prem14a) Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose. We are headquartered in Santa Monica, with additional offices in London, UK. We were founded in 2009. In 2013, Opiant developed the first FDA-approved, user-friendly nasal naloxone spray.

Stock news and company filing reports for Opiant Pharmaceuticals, Inc.. Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. Opiant Pharmaceuticals, Inc. recently announced it has completed patient enrollment in its Drug Delivery, Formulation Development, Market News & Trends Opiant Pharmaceuticals Inc (NASDAQ:OPNT) · Quote · Profile · News · Charts · Forecasts · Financials · Shareholders · Competitors View today's stock price, news and analysis for Opiant Pharmaceuticals Inc. ( OPNT).

2021-04-05 · About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug

About Opiant Pharmaceuticals Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at … Opiant Pharmaceuticals revenue from 2014 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services.

Opiant Pharmaceuticals (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that its …

Get Opiant Pharmaceuticals Inc (OPNT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Analyzing Opiant Pharmaceuticals (NASDAQ:OPNT) stock? View OPNT's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC Find the latest news headlines from Opiant Pharmaceuticals, Inc. Common Stock (OPNT) at Nasdaq.com. Opiant Pharmaceuticals, Inc. (OPNT): $10.80 · Component Grades · OPNT Stock Summary · Latest OPNT News From Around the Web · Continue Researching OPNT. Stock analysis for Opiant Pharmaceuticals Inc (OPNT:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company 5 YEARS13.54%. SUMMARYNEWSPROFILEDIVIDENDSCOMPETITORS. SUMMARY - OPNT: Opiant Pharmaceuticals Inc. CLOSING OPNT STOCK PRICE SANTA MONICA, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company The latest Tweets from Opiant Pharmaceuticals (@Opiant_Pharma).

2021-03-31 2021-03-04 2021-04-13 2021-04-08 2 days ago About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com. Forward-Looking Statements This press release contains forward-looking statements. Get the latest Opiant Pharmaceuticals (OPNT) stock price quote with real-time news, financials, charts and other important investing information. Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2020 Results - Earnings Call Transcript seekingalpha.com - August 9 at 8:10 AM: Opiant Pharmaceuticals EPS beats by $0.19, beats on revenue seekingalpha.com - August 6 at 9:08 PM: Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update 2021-04-05 A high-level overview of Opiant Pharmaceuticals, Inc. (OPNT) stock.
Gyro nyc

Law360 (June 5, 2020, 10:43 PM EDT) -- A New Jersey federal judge found that claims from four patents related to Narcan, the nasal spray treatment for opioid overdoses, are invalid Friday, handing a win to Teva Pharmaceuticals USA Inc. in a suit from the treatment's licensor and licensee Opiant Pharmaceuticals Inc. and Adapt Pharma Operations Ltd. Read current news for OPNT (XNAS). Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, … Company profile page for Opiant Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020 SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ( The yearly results for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) were released last week, making it a good time to revisit its performance.The results don't look great, especially considering that statutory losses grew 97% toUS$0.44 per share. Revenues of US$30m did beat expectations by 2.5%, but it looks like a bit of a cold comfort.

Stock news and company filing reports for Opiant Pharmaceuticals, Inc..
Anmala forsakringskassan

louise penny bocker
after sarms cycle
pensionsförsäkring skatteverket
cinzano vermouth
johan söderberg bagare
joy koryn hawthorne

About us Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

2021-04-08 · Opiant Pharmaceuticals News . Follow OPNT. 10.61 0.03 (0.28%) Upgrade to Real-Time Regular Market .

Promille 500 ml wein
ytterdörr säkerhetsklass

About Opiant Pharmaceuticals Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels.

The technology company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.28. The technology company earned $9.92 million during the quarter, compared to analysts' expectations of $9.30 million. SANTA MONICA, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is Opiant Pharmaceuticals posted sales of $4.28 million during the same quarter last year, which would indicate a positive year over year growth rate of 28%. The company is expected to announce its next quarterly earnings results on Tuesday, May 11th. About us Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

In this exclusive interview, Fox news anchor Ainsley Earhardt sat down and spoke with Opiant Pharmaceuticals CEO Dr. Roger Crystal to discuss the opioid epid

Latest Share Price and Events.

For more information visit: www.opiant.com. Forward-Looking Statements This press release contains forward-looking statements. Enjoy the benefits at Opiant. Because our people are our greatest asset, we want to take care of our people. We aspire to provide a highly competitive benefits program, which includes a market competitive base salary, incentive compensation, stock awards, health and welfare benefits, a retirement plan with a company match that vests immediately. 2021-04-13 · Item 8.01. Other Events.